Compare KRUS & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KRUS | ANL |
|---|---|---|
| Founded | 2008 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 650.6M | 731.6M |
| IPO Year | 2019 | 2022 |
| Metric | KRUS | ANL |
|---|---|---|
| Price | $46.46 | $10.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 1 |
| Target Price | ★ $81.11 | $20.00 |
| AVG Volume (30 Days) | ★ 374.4K | 129.2K |
| Earning Date | 04-07-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 79.75 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $282,763,000.00 | N/A |
| Revenue This Year | $20.50 | $36.02 |
| Revenue Next Year | $20.68 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 18.88 | N/A |
| 52 Week Low | $42.62 | $0.88 |
| 52 Week High | $95.98 | $17.25 |
| Indicator | KRUS | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 40.40 | 40.94 |
| Support Level | $42.81 | $6.92 |
| Resistance Level | $58.75 | $12.59 |
| Average True Range (ATR) | 2.98 | 1.15 |
| MACD | -0.49 | -0.11 |
| Stochastic Oscillator | 24.98 | 26.07 |
Kura Sushi USA Inc is a technology-enabled Japanese restaurant concept that provides guests with a distinctive dining experience by serving authentic Japanese cuisine through an engaging revolving sushi service model. The company operates a chain of sushi restaurants across the United States serving freshly prepared Japanese cuisine using high-quality ingredients that are free from artificial seasonings, sweeteners, colorings, and preservatives. The company operates a network of dine-in locations across the U.S. states and Washington, DC.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.